POCT Molecular Diagnostics Leader Zhiwe Microbial Completes RMB 100 Million Series A Financing Led by QingSong Capital

Recently, Beijing BOE Microbial Technology Co., Ltd. (hereinafter referred to as “Genewise Bio”) announced the completion of its Series A financing, with a total amount reaching RMB 100 million. This round of financing was led byLed by China Tsing Song Investment Ltd, with participation from Wuhe Investment, Beijing Aeonmed Co.,Ltd., and PinnaclesPending co-investment from senior industry partners. Investors in this round have strong confidence in the development prospects of Genewise Bio and will engage in deep collaboration to jointly build a platform for technology transfer and product development. They will also fully support the acceleration of Genewise Bio’s commercialization process both domestically and internationally, injecting strong momentum into its growth and continuously strengthening its leading position in the field of POCT molecular diagnostics.

Genewise Bio, established in 2021, is a high-tech enterprise incubated by BOE Technology Group and specialized in molecular diagnostics. Adhering to its mission of “Molecular Diagnostics for All,” the company has successfully built a fully integrated, independently developed R&D and production system encompassing microfluidic chips, diagnostic reagents, and detection instruments. It is committed to creating innovative point-of-care testing (POCT) molecular diagnostic platforms for pathogen detection, antimicrobial resistance gene testing, and maternal and child health, thereby empowering the development of China’s precision medicine system and tiered diagnosis and treatment framework through technological innovation. Genewise Bio boasts a robust, interdisciplinary team combining medical and engineering expertise, with core members holding doctoral or master’s degrees from prestigious institutions worldwide, including Princeton University, Tsinghua University, Peking University, and the Chinese Academy of Sciences.

Genewise Bio has obtained Class III medical device registration certificates from the National Medical Products Administration (NMPA) and CE certification for more than 20 products.Notably, the approval and market launch of its core molecular POCT platform—the NAT-3000 Fully Automated Nucleic Acid Amplification Analyzer—and its first reagent kit, the Novel Coronavirus (2019-nCoV) and Influenza A/B Virus Nucleic Acid Combined Detection Kit (Fluorescent PCR Method), mark the official entry of China’s “gold standard” nucleic acid testing into a new era of 30-minute turnaround times. The products have been installed in numerous top-tier Grade IIIA hospitals and children’s medical centers across various regions. Their performance, rigorously tested during peak sample volumes in the autumn and winter seasons, has earned consistent recognition and acclaim from industry experts in laboratory medicine and clinical practice. Furthermore, Genewise Bio has undertaken multiple key provincial and municipal R&D projects and continuously enhanced its R&D and innovation capabilities through an “industry-academia-research-application” collaborative model. The company has established product development and clinical research collaborations with many renowned clinical and scientific institutions, covering multiple fields and disease types.

The successful completion of this financing round not only marks a milestone transformation and breakthrough in the governance structure of Genewise Bio, but also demonstrates the firm confidence of the management team, industry capital, and the industrial sector in the POCT molecular diagnostics track.

Zhang Yu, Executive Vice President of BOE Group, Chairman and CEO of Smart Medical Engineering Business: Guided by the "Internet of Screens" strategy, BOE Health, as a key initiative of the BOE Group, deeply integrates technology with medicine. It is committed to building a health IoT ecosystem centered on health management, driven by medical-engineering products, and supported by digital hospitals and elderly care communities. This strategic layout not only establishes an integrated chain spanning prevention, treatment, and rehabilitation but also provides high-quality, convenient healthcare services to a broad user base. Adhering to a people-centric development philosophy, BOE Health focuses on three major sectors—smart terminals and systems, molecular testing, and regenerative medicine—through innovation in medical-engineering integration. By implementing a series of market-oriented reforms, it has successfully incubated Genewise Bio, which centers its business on molecular testing and is dedicated to accelerating the development of genetic and molecular diagnostic technologies, further demonstrating BOE Health's innovative strength in the field of medical technology.

Dr. Zhang Yufan, Chairman and General Manager of Genewise Bio: Against the backdrop of a broader macroeconomic downturn and the IVD industry’s post-pandemic period of adjustment, the Genewise Bio team has remained strategically focused on the emerging direction of technological iteration toward POCT-enabled molecular diagnostics. We have consistently been dedicated to serving the new clinical demands led by POCT molecular diagnostic products, and we maintain a positive and firm outlook on the future of the domestic and international molecular diagnostics markets. “POCT-enabled molecular diagnostic solutions” have revolutionarily redefined the dimensions of time, space, automation, and quality control in molecular diagnostics, representing an inevitable trend in technological development. All molecular diagnostic assays deserve to be reimplemented and thrive on POCT platforms. We are delighted that this financing round was led by top-tier investment firm China Tsing Song Investment Ltd, and garnered favor from other outstanding investment institutions and industrial partners. The Genewise Bio team will move forward hand in hand with all our new and existing shareholders, continuously bringing more surprises and breakthroughs to the molecular diagnostics industry.

Li Jing, Project Lead at China Tsing Song Investment LtdStatement: As a key niche segment driving the transformation and upgrading of the in vitro diagnostics (IVD) industry, molecular diagnostic point-of-care testing (POCT) has long been under the close watch of China Tsing Song Investment. Over the past two years, despite a challenging external environment, we have highly recognized Genewise Bio’s team for their profound insights into the diagnostics industry, differentiated product portfolio strategy, and efficient execution. With innovative DNA and strong expertise in molecular microfluidics technology and manufacturing, Genewise Bio has successfully built an innovative POCT molecular diagnostics technology platform and product lineup, including solutions for infectious disease detection and antimicrobial resistance gene testing. The performance of these products has gained recognition from numerous top-tier clinical institutions and experts. China Tsing Song Investment remains committed to continuously focusing on and supporting the industrial development and innovation of its portfolio companies alongside strategic partners. We are honored to be a shareholder of Genewise Bio and look forward to the company unleashing greater vitality with the support of this round of financing and optimized governance structure. Together with all stakeholders, we aim to accelerate product registration and commercialization, consolidate its industry-leading position, provide customers with more precise and convenient solutions, and contribute to the high-quality development of China’s healthcare industry.

Jia Nan, Dean of Aeonmed Medical Engineering Research InstituteIt was stated that the molecular POCT sector is akin to the “pearl in the crown” of the IVD field. Despite the seemingly fierce competition, Genewise Bio’s team has achieved significant breakthroughs and innovations in technology and manufacturing processes, enabling its products to stand out and making its profitability model more practical and viable. From the perspectives of industrialization and the integrated development of medicine and engineering, Beijing Aeonmed Co., Ltd. recognizes Genewise Bio’s comprehensive capabilities in product development, quality control, and market promotion. Aeonmed is optimistic about Genewise Bio’s potential to become a leader in this sector and is willing to support its rapid and steady growth, thereby injecting new vitality into China’s healthcare industry, contributing new elements to national confidence, and creating more opportunities for human life and health.

Tsing Song Capital is a private equity investment firm specializing in biotechnology and healthcare. Its management team possesses extensive experience in the medical industry and private equity investment. Tsing Song Capital is committed to growing alongside the most innovative biomedical enterprises, driving technological and commercial innovation in China’s life sciences and healthcare sectors. Adhering to a research-driven investment approach, the firm deeply engages in the development of its portfolio companies, focusing on biotechnology, innovative drugs, novel medical devices, precision medicine and services, as well as the intersection of the broader health industry with frontier technologies. Since its inception, Tsing Song Capital has completed investments in multiple star projects across various niche sectors, including SinoCellTech (688520.SH), United Imaging Healthcare (688271.SH), Sino Biological (301047.SZ), Giant Biogene (02367.HK), and Bio-Link Pharma.

Wuhe Investment is a venture capital firm deeply rooted in the biopharmaceutical and medical device sectors, boasting nearly two decades of experience in the healthcare industry. Leveraging its strong team, diversified resources, and profound industry expertise, Wuhe Investment has not only achieved remarkable success in financial investments but also effectively advanced the implementation and execution of key initiatives—such as channel development, market cultivation, and partner growth—through meticulous resource integration strategies. As an investment institution, Wuhe Investment is further committed to resource sharing and strategic collaboration, establishing itself as a vital partner within the industry.

Aeonmed is a globally leading medical device manufacturer, with its business spanning the fields of healthcare, wellness, and biotechnology. Its product portfolio covers anesthesia, respiratory care, sleep therapy, oxygen therapy, emergency care, and self-testing/rapid testing. In terms of global ecological layout, Aeonmed has established 28 provincial branches and 185 municipal offices in China, while also setting up eight international subsidiaries across North and South America, Europe, Asia-Pacific, the Middle East, and Africa, covering 30 international business regions. Currently, more than 60 of its products have obtained regulatory certifications for medical devices, including approvals from China’s NMPA, the U.S. FDA, the EU CE marking, Brazil’s BGMP, and Japan’s PMDA. Adhering to its brand mission of “Sincerely Safeguarding Life,” Aeonmed is committed to providing trustworthy medical products and solutions to customers worldwide.

Shanghai Pinnacles Medical Technology Co., Ltd. is headquartered in Shanghai, with R&D, production, and commercial centers established in the Yangtze River Delta, the Pearl River Delta, Beijing, and other regions. Since its inception, Pinnacles has remained dedicated to product development in the fields of smart laboratory testing and precision diagnostics. The company is committed to integrating and innovating in vitro diagnostic technologies—such as biochemistry, immunology, and molecular diagnostics—with enabling cross-disciplinary technologies including automation, robotics, the Internet of Things (IoT), big data, and artificial intelligence (AI), thereby creating globally leading solutions for “unmanned smart clinical laboratories.”